07:00 , Aug 17, 2009 |  BC Week In Review  |  Company News

Antisoma, Bryan Oncor deal

Antisoma granted cancer company Bryan Oncor an exclusive, worldwide license to develop and commercialize P2045. The somatostatin receptor-binding peptide combined with rhenium-188 isotope has completed a Phase I trial to treat non-small cell lung cancer...